What is BPC-157?
BPC-157, short for Body Protection Compound 157, is a synthetic pentadecapeptide composed of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It was originally isolated as a partial sequence of a larger protein found in human gastric juice, and has since become one of the most extensively studied peptides in preclinical wound healing and tissue protection research.
BPC-157 is notable in scientific literature for its reported stability across a wide pH range, including the acidic environment of the stomach — a property that distinguishes it from many other research peptides which require parenteral administration for laboratory study.
This article is intended as a scientific overview for laboratory researchers. All compounds discussed are sold strictly for in-vitro research and are not for human consumption.
Discovery and Background
BPC (Body Protection Compound) was first described in scientific literature in the 1990s by researchers studying organoprotective peptides in gastric juice. The original BPC was a much larger molecule, and BPC-157 represents the smallest fragment that retained the parent compound's reported biological activity in animal models.
Over three decades, BPC-157 has accumulated a substantial body of preclinical literature — primarily in rodent models — examining its effects across a range of injury and tissue-stress conditions. PubMed currently indexes hundreds of peer-reviewed papers on BPC-157, with most originating from research groups in Croatia, Japan, and the United States.
It's important to note that despite the volume of preclinical literature, BPC-157 has not been the subject of large-scale human clinical trials, and is not approved by the FDA or any major regulatory body for therapeutic use. It remains a research compound.
Proposed Mechanisms of Action
The exact mechanism by which BPC-157 produces its observed effects in animal studies remains an active area of investigation. Current research literature describes several pathways that may contribute to the compound's reported activity.
Angiogenesis and the VEGFR2 Pathway
One of the most studied proposed mechanisms involves BPC-157's interaction with vascular endothelial growth factor receptor 2 (VEGFR2). Studies in rodent models have suggested that BPC-157 may upregulate VEGFR2 signaling, potentially contributing to angiogenesis (the formation of new blood vessels) in tissues undergoing repair processes.
This proposed mechanism has been examined in tendon, ligament, and muscle tissue research, where increased vascularization is believed to support tissue remodeling.
Growth Hormone Receptor Modulation
Some preclinical studies have reported that BPC-157 may influence growth hormone receptor (GHR) expression in fibroblasts. This has been proposed as a contributing factor to the compound's observed effects on connective tissue research models.
Nitric Oxide System Interaction
Multiple studies have examined BPC-157's interaction with the nitric oxide (NO) system. Animal research suggests the compound may modulate NO synthesis in a context-dependent manner — potentially explaining its varied effects observed across different tissue types and injury models in laboratory studies.
Dopaminergic and Serotonergic Systems
A smaller body of preclinical literature has examined potential interactions between BPC-157 and central neurotransmitter systems, including dopamine and serotonin pathways, in rodent behavioral models.
Current Research Areas
The published BPC-157 literature spans several distinct research directions. The following list represents research interest areas in the published literature — not validated therapeutic uses.
- Tendon and ligament repair models: Studies in rats have examined BPC-157's effects on Achilles tendon transection models and medial collateral ligament injury models
- Gastrointestinal tissue research: Models of gastric ulcer, inflammatory bowel disease, and intestinal anastomosis healing
- Bone healing models: Rodent studies of segmental bone defect repair
- Skin wound research: Topical and systemic application studies in cutaneous wound healing models
- Neuroprotection models: Traumatic brain injury and spinal cord injury research in animal models
- Cardiovascular research: Studies examining BPC-157 in models of cardiac ischemia and reperfusion
Researchers interested in this literature can find primary sources via PubMed searches for "BPC-157", which will return current peer-reviewed publications.
Stability and Laboratory Handling
BPC-157 is typically supplied as a lyophilized (freeze-dried) white powder for laboratory use. The compound is reported to be relatively stable compared to many research peptides, but proper handling remains important for maintaining research integrity.
General Handling Considerations
- Lyophilized form storage: Refrigerated at 2-8°C is acceptable for short-term storage; frozen at -20°C is recommended for long-term storage
- Reconstitution: BPC-157 is typically reconstituted with bacteriostatic water for injection (BWFI) for laboratory studies. Sterile water can also be used for very short-term experiments
- Reconstituted shelf-life: Once reconstituted, the solution is generally considered stable for several weeks under refrigeration in published protocols, though specific stability data should be confirmed for each research application
- Light sensitivity: Reconstituted solutions should be protected from prolonged light exposure
- Avoid repeated freeze-thaw cycles: These can degrade peptide integrity
Verifying Purity
For research reproducibility, researchers should obtain BPC-157 from suppliers who provide a Certificate of Analysis (COA) documenting purity by HPLC and identity confirmation by mass spectrometry. Purity above 99% is the industry research standard. Look for batch-specific COAs rather than generic spec sheets.
At Prime Peptide Solutions, every batch ships with a third-party verified COA. Researchers can browse our published COAs or view our BPC-157 product page for current available variants.
Frequently Asked Research Questions
Is BPC-157 the same as the natural BPC peptide found in gastric juice?
No. BPC-157 is a synthetic 15-amino-acid fragment of a larger natural BPC protein originally identified in gastric juice. The synthetic fragment is what is studied in modern peptide research literature.
What is the difference between BPC-157 and BPC-157 arginate?
BPC-157 arginate (sometimes called "BPC-157 arginine salt") is a salt form of BPC-157. The arginate form is reported to have improved aqueous solubility and shelf stability in some preparations. The active peptide sequence is identical between the two forms.
Is BPC-157 approved for human use?
No. BPC-157 has not been approved by the FDA or any major regulatory body for therapeutic use in humans. It is sold as a research compound for laboratory use only. Materials sold by Prime Peptide Solutions are explicitly not intended for human consumption.
What purity should a research-grade BPC-157 have?
Research-grade BPC-157 should be characterized at greater than 99% purity by HPLC, with identity confirmed by mass spectrometry. The COA should report batch-specific values, not just specification limits.
How is BPC-157 typically administered in animal studies?
The published literature describes a range of administration routes in animal research, including intraperitoneal, subcutaneous, and oral routes. Researchers should consult the specific protocols described in published literature relevant to their research model.
Conclusion
BPC-157 represents one of the most extensively studied research peptides in preclinical literature, with proposed mechanisms involving angiogenesis, growth factor signaling, and nitric oxide pathway modulation. Despite the breadth of animal model research, the compound remains in research-only status and has not been validated through large-scale human clinical trials.
For researchers working with BPC-157, sourcing from suppliers who provide third-party verified Certificates of Analysis remains the most important step in ensuring experimental reproducibility. Proper storage, careful reconstitution, and protocol-specific handling all contribute to research integrity.
Disclaimer: This article is provided for educational and research purposes only. The information contained herein is a summary of publicly available scientific literature and does not constitute medical advice. BPC-157 and all peptide compounds sold by Prime Peptide Solutions are intended strictly for laboratory research and are not for human consumption, in vivo human use, or therapeutic application. Researchers are responsible for compliance with all applicable regulations governing peptide use in their jurisdiction.
References & Further Reading
- PubMed: Current peer-reviewed BPC-157 literature
- Sikiric, P. et al. — Foundational BPC-157 research from the University of Zagreb research group (multiple publications, 2000s–present)
- For COAs and product specifications, see our published Certificates of Analysis